New Methods and Future Technology

Editor(s): Ronco C. (Vicenza) 
Rosner M.H. (Charlottesville, Va.) 
Table of Contents
Vol. 171, 2011
Section title: Lipid Disorders and Metabolism
Ronco C, Rosner MH (eds): Hemodialysis: New Methods and Future Technology. Contrib Nephrol. Basel, Karger, 2011, vol 171, pp 135–142

Lipid Abnormalities in Patients with Chronic Kidney Disease

Keane W.F. · Tomassini J.E. · Neff D.R.
aUniversity of Minnesota School of Medicine, and bMerck Sharp & Dohme Corp., Whitehouse Station, N.J., USA

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Cardiovascular disease is increased in patients with chronic kidney disease (CKD) and is the principle cause of morbidity and mortality in these patients. Dyslipidemia, while common in these patients, is usually not characterized by elevated cholesterol, except in those patients with massive proteinuria. Qualitatively, increased triglycerides and reduced high-density lipoproteins (HDL) are most frequently described. Extensive abnormalities in the metabolism of apolipoprotein (apo) B-containing lipoproteins have been demonstrated, including those derived from the gut (apoB-48) as well as those derived from hepatic synthesis (apoB-100). Decreased enzymatic delipidation, in addition to reduced receptor removal of these lipoproteins, results in increased concentrations of these apoB-containing moieties, and in particular, their atherogenic remnants. Abnormalities in apoA-containing lipoproteins are also present and these changes may contribute not only to the lower levels of HDL seen, but also to the proinflammatory state that is frequently present in CKD patients. As a result, therapeutic strategies designed to modify atherosclerotic-caused outcomes in CKD may require multiple approaches.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. McCullough PA: Cardiovascular disease in chronic kidney disease from a cardiologist's perspective. Curr Opin Nephrol Hypertens 2004;13:591-600
  2. Ronco C, Haapio M, House AA, Anavekar N, Bellomo R: Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-1539
  3. National Kidney Foundation: K/ DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003;41:(Suppl 3)S1-S92
  4. Kaysen GA: Lipid and lipoprotein metabolism in chronic kidney disease. J Ren Nutrit 2009;19:73-77
  5. Vaziri ND, Norris K: Lipid disorders and their relevance to outcomes in chronic kidney disease. Blood Purif 2011;31:189-196
  6. Vaziri ND: Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006;290:F262-F272
  7. Lacquaniti A, Bolignano D, Donato V, Bono C, Razio MR, Buemi M: Alterations of lipid metabolism in chronic nephropathies: mechanisms, diagnosis and treatment. Kidney Blood Press Res 2010;33:100-110
  8. Kruit JK, Groen AK, van Berkel TJ, Kuipers F: Emerging roles of the intestine in control of cholesterol metabolism. World J Gastroenterol 2006;12:6429-6439
  9. Redgrave TG: Chylomicron metabolism. Biochem Soc Trans 2004;32:79-82
  10. Turley SD, Dietschy JM: Sterol absorption by the small intestine. Curr Opin Lipidol 2003;14:233-240
  11. Vaziri ND, Liang KH: Down-regulation of tissue lipoprotein lipase expression in experimental chronic renal failure. Kidney Int 1996;50:1928-1935
  12. Kim C, Vaziri ND: Down-regulation of hepatic LDL receptor-related protein (LRP) in chronic renal failure. Kidney Int 2005;67:1028-1032
  13. Liang KH, Oveisi F, Vaziri ND: Role of secondary hyperparathyroidism in the genesis of hypertriglyceridemia and VLDL receptor deficiency in chronic renal failure. Kidney Int 1998;53:626-630
  14. Vaziri ND, Liang KH: Down-regulation of VLDL receptor expression in chronic experimental renal failure. Kidney Int 1997;51:913-919
  15. Vaziri ND, Liang KH: Down-regulation of hepatic LDL receptor expression in experimental nephrosis. Kidney Int 1996;50:887-893
  16. Sato T, Liang KH, Vaziri ND: Protein restriction and AST-120 improve lipoprotein lipase and VLDL receptor in focal glomerulosclerosis. Kidney Int 2003;64:1780-1786
  17. Klin M, Smogorzewski M, Ni ZM, Zhang GX, Massry SG: Abnormalities in hepatic lipase in chronic renal failure - role of excess parathyroid hormone. J Clin Invest 1996;97:2167-2173
  18. Liang K, Vaziri ND: Down-regulation of hepatic lipase expression in experimental nephrotic syndrome. Kidney Int 1997;51:1933-1937
  19. Deighan CJ, Caslake MJ, McConnell M, Boulton-Jones JM, Packard CJ: The atherogenic lipoprotein phenotype: small dense LDL and lipoprotein remnants in nephrotic range proteinuria. Atherosclerosis 2001;157:211-220
  20. St-Pierre AC, Cantin B, Dagenais GR, Mauriege P, Bernard PM, Despres JP, Lamarche B: Low-density lipoprotein subfractions and the long-term risk of ischemic heart disease in men: 13-year follow-up data from the Quebec Cardiovascular Study. Arterioscler Thromb Vasc Biol 2005;25:553-559
  21. Kaysen GA: New insights into lipid metabolism in chronic kidney disease: what are the practical implications?. Blood Purif 2009;27:86-91
  22. Kronenberg F, Kuen E, Ritz E, Junker R, Konig P, Kraatz G, Lhotta K, Mann JF, Muller GA, Neyer U, Riegel W, Reigler P, Schwenger V, von Eckardstein A: Lipoprotein(a) serum concentrations and apolipoprotein(a) phenotypes in mild and moderate renal failure. J Am Soc Nephrol 2000;11:105-115
  23. Kuboyama M, Ageta M, Ishihara T, Fujiura Y, Kashio N, Ikushima I: Serum lipoprotein(a) concentration and Apo(a) isoform under the condition of renal dysfunction. J Atheroscler Thromb 2003;10:283-289
  24. Danesh J, Collins R, Peto R: Lipoprotein(a) and coronary heart disease. Meta-analysis of prospective studies. Circulation 2000;102:1082-1085
  25. Vaziri ND, Deng G, Liang K: Hepatic HDL receptor, SR-B1 and Apo A-I expression in chronic renal failure. Nephrol Dial Transplant 1999;14:1462-1466
  26. Ansell BJ, Navab M, Hama S, Kamranpour N, Fonarow G, Hough G, Rahmani S, Mottahedeh R, Dave R, Reddy ST, Fogelman AM: Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment. Circulation 2003;108:2751-2756
  27. Moradi H, Pahl MV, Elahimehr R, Vaziri ND: Impaired antioxidant activity of high-density lipoprotein in chronic kidney disease. Transl Res 2009;153:77-85
  28. Zhao Y, Marcel YL: Serum albumin is a significant intermediate in cholesterol transfer between cells and lipoproteins. Biochemistry 1996;35:7174-7180
  29. Martinez LO, Jacquet S, Esteve JP, Rolland C, Cabezon E, Champagne E, Pineau T, Georgeaud V, Walker JE, Terce F, Collet X, Perret B, Barbaras R: Ectopic beta-chain of ATP synthase is an apolipoprotein A-I receptor in hepatic HDL endocytosis. Nature 2003;421:75-79
  30. Navab M, Anantharamaiah GM, Reddy ST, Van Lenten BJ, Ansell BJ, Fogelman AM: Mechanisms of disease: proatherogenic HDL - an evolving field. Nat Clin Pract Endocrinol Metab 2006;2:504-511

Pay-per-View Options
Direct payment This item at the regular price: USD 33.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 23.00